Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16862931 | 0.87 | TDP1 (0.52) | TDP1VCAM1DPP4L3MBTL1CASP6 | |
| SCHEMBL3882207 | 0.85 | TDP1 (0.60) | TDP1VCAM1CASP6TSHRMAPK1 | |
| SCHEMBL2030471 | 0.85 | TDP1 (0.60) | TDP1VCAM1DPP4L3MBTL1CASP6 | |
| 2,3,6-Trichlorobenzoic Acid SCHEMBL9531555 | 0.85 | TDP1 (0.47) | TDP1VCAM1DPP4L3MBTL1CASP6 | |
| SCHEMBL27562624 | 0.84 | TDP1 (0.44) | TDP1VCAM1DPP4L3MBTL1CASP6 | |
| SCHEMBL5725938 | 0.84 | TDP1 (0.58) | TDP1VCAM1TSHRMAPK1KMT2A | |
| SCHEMBL3886618 | 0.84 | TDP1 (0.58) | TDP1VCAM1L3MBTL1TSHRMAPK1 | |
| SCHEMBL17368792 | 0.84 | DPP4 (0.60) | TDP1VCAM1DPP4L3MBTL1CASP6 | |
| SCHEMBL913380 | 0.82 | TDP1 (0.47) | TDP1VCAM1L3MBTL1CASP6TSHR | |
| SCHEMBL6137884 | 0.82 | LMNA (0.51) | TDP1L3MBTL1CASP6TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-111320548-B | Synthesis method of anticancer drug intermediate 2-fluoro-3-methyl aminobenzoate | 浦拉司科技（上海）有限责任公司 | 2022-10-18 | — | — | CN | claimed |
| EP-2520176-B1 | Method for increasing the nutritional value of rapeseed and rape products with decreased oil content | ROP REPCE OLAJ PELLET KFT (HU) | 2019-02-20 | — | — | EP | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120282369-A1 | METHOD FOR INCREASING THE NUTRITIONAL VALUE OF RAPESEED AND RAPE PRODUCTS WITH DECREASED OIL CONTENT | ROP REPCE-OLAJ-PELLET KFT. (HU) | 2012-11-08 | — | — | US | claimed |
| EP-2520176-A1 | Method for increasing the nutritional value of rapeseed and rape products with decreased oil content | ROP Repce-olaj-pellet Kft. (HU) | 2012-11-07 | — | — | EP | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250228239-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240279233-A1 | MACROCYCLIC TAK1 INHIBITORS | AQILION AB (SE) | 2024-08-22 | — | — | US | disclosed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| CN-118044519-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-4363422-A1 | MACROCYCLIC TAK1 INHIBITORS | Aqilion AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-11944099-B2 | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto | CORTEVA AGRISCIENCE LLC (US) | 2024-04-02 | — | — | US | disclosed |
| CN-117561262-A | Macrocyclic TAK1 inhibitors | 阿奎利恩有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-110072842-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| CN-116768791-A | Amide aldehyde dehydrogenase agonist, synthesis method and application thereof | 中国人民解放军海军军医大学 | 2023-09-19 | — | — | CN | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| EP-4142707-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023275199-A1 | MACROCYCLIC TAK1 INHIBITORS | AQILION AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| EP-4073242-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | Kumquat Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-111320548-B | Synthesis method of anticancer drug intermediate 2-fluoro-3-methyl aminobenzoate | 浦拉司科技（上海）有限责任公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-111320548-B | Synthesis method of anticancer drug intermediate 2-fluoro-3-methyl aminobenzoate | 浦拉司科技（上海）有限责任公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115103907-A | Compositions and methods for enhancing immune activity | 金橘生物科技公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3964495-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND COMPOSITIONS, AND PROCESSES, RELATED THERETO | Dow AgroSciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2021119554-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210161144-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2021-06-03 | — | — | US | disclosed |
| US-10993440-B2 | Molecules having pesticidal utility, and intermediates, compositions, and processes related thereto | DOW AGROSCIENCES LLC (US) | 2021-05-04 | — | — | US | disclosed |
| CN-111320548-A | Synthesis method of anticancer drug intermediate 2-fluoro-3-methyl aminobenzoate | 浦拉司科技（上海）有限责任公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-111320548-A | Synthesis method of anticancer drug intermediate 2-fluoro-3-methyl aminobenzoate | 浦拉司科技（上海）有限责任公司 | 2020-06-23 | — | — | CN | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20190166847-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190150452-A1 | MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-10258045-B2 | Molecules having pesticidal utility and intermediates, compositions and processes related thereto | DOW AGROSCIENCES LLC (US) | 2019-04-16 | — | — | US | disclosed |
| EP-2520176-B1 | Method for increasing the nutritional value of rapeseed and rape products with decreased oil content | ROP REPCE OLAJ PELLET KFT (HU) | 2019-02-20 | — | — | EP | disclosed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180098541-A1 | MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2018-04-12 | — | — | US | disclosed |
| US-9580412-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-28 | — | — | US | disclosed |
| US-9580412-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-28 | — | — | US | disclosed |
| US-9580412-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-28 | — | — | US | disclosed |
| US-9526732-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-15 | — | — | US | disclosed |
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | disclosed |
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | disclosed |
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | disclosed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | disclosed |
| US-9364466-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9340574-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2771329-B1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RES & DEV (FR) | 2016-03-16 | — | — | EP | disclosed |
| EP-2714688-B1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150374708-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-12-31 | — | — | US | disclosed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-08-27 | — | — | US | disclosed |
| EP-2771334-B1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RES & DEV (FR) | 2015-08-19 | — | — | EP | disclosed |
| US-9090596-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-07-28 | — | — | US | disclosed |
| US-9090596-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-07-28 | — | — | US | disclosed |
| US-9090596-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-07-28 | — | — | US | disclosed |
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8980911-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140309208-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-16 | — | — | US | disclosed |
| US-20140309208-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-16 | — | — | US | disclosed |
| US-20140309208-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-16 | — | — | US | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| WO-2014055768-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2013061005-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013061004-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | disclosed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2012160464-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-29 | — | — | WO | disclosed |
| US-20120282369-A1 | METHOD FOR INCREASING THE NUTRITIONAL VALUE OF RAPESEED AND RAPE PRODUCTS WITH DECREASED OIL CONTENT | ROP REPCE-OLAJ-PELLET KFT. (HU) | 2012-11-08 | — | — | US | disclosed |
| EP-2520176-A1 | Method for increasing the nutritional value of rapeseed and rape products with decreased oil content | ROP Repce-olaj-pellet Kft. (HU) | 2012-11-07 | — | — | EP | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| WO-2012118492-A1 | HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2493865-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2470538-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025940-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003859-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2265574-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1956054-B1 | Phase change ink | XEROX CORP (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1497278-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | XANTHUS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111280-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1703909-B1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| EP-1357909-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080187664-A1 | Phase change inks containing colorant compounds | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080184910-A1 | Mixture of basic dye and wax | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| WO-2008016661-A2 | MORPHOLINO COMPOUNDS FOR TREATING INFLAMMATORY AND DEMYELINATING DISEASES AND CANCERS | XANTHUS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016665-A2 | IMIDAZOACRIDINE COMPOUNDS FOR TREATING FLT3 -MEDIATED DISORDERS | XANTHUS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070254312-A1 | Protein Kinase Inhibitors and Methods for Identiying Same | NATIONAL INSTITUTES OF HEALTH | 2007-11-01 | — | — | US | disclosed |
| US-7279484-B2 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2007-10-09 | — | — | US | disclosed |
| EP-1703909-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-27 | — | — | EP | disclosed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060084661-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| CN-1724532-A | Colorant compound | XEROX CORP (US) | 2006-01-25 | — | — | CN | disclosed |
| EP-1357909-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050250796-A1 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2005-11-10 | — | — | US | disclosed |
| CN-1690040-A | 3,5-dichloroaniline preparing process | YANCHENG GUANGXIN CHEMICAL CO (CN) | 2005-11-02 | — | — | CN | disclosed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1515956-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | disclosed |
| EP-1515956-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Smithkline Beecham (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023261-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| EP-1497278-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040132694-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-07-08 | — | — | US | disclosed |
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | SMITHKLINE BEECHAM CORPORATION | 2004-06-10 | — | — | US | disclosed |
| EP-1185271-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1383488-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003104209-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6664263-B2 | Potent unsymmetrical DNA bifunctional intercalators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-16 | — | — | US | disclosed |
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225125-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030220392-A1 | Fatty acid synthase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1357909-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203916-A1 | 1,8-NAPHTHALIMIDE IMIDAZO{4,5,1-DE}ACRIDONES WITH ANTI-TUMOR ACTIVITY | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEARTMENT OF | 2003-10-30 | — | — | US | disclosed |
| WO-2003087085-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1265898-B1 | 1,8-NAPHTHALIMIDE IMIDAZO 4,5,1- i de /i ]ACRIDONES WITH ANTI-TUMOR ACTIVITY | US GOV HEALTH & HUMAN SERV (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-1237548-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1299376-A1 | FATTY ACID SYNTHASE INHIBITORS | Smithkline Beecham (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6498187-B1 | SUCH AS 2'-(6-CHLOROPIPERONYL)-3-(2,6-DICHLOROBENZYLOXY)-CINNAMIC ACID; ANTIBIOTICS | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| EP-1265898-A2 | 1,8-NAPHTHALIMIDE IMIDAZO 4,5,1- i de /i ]ACRIDONES WITH ANTI-TUMOR ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1206464-A4 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002079122-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1237548-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002067919-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1206464-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1185271-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001090099-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001066545-A2 | 1,8-NAPHTHALIMIDE IMIDAZO[4,5,1-de]ACRIDONES WITH ANTI-TUMOR ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001034141-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001014363-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000076515-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0750612-B1 | ACRIDONE-DERIVED BISINTERCALATORS AS CHEMOTHERAPEUTIC AGENTS | US HEALTH (US) | 1999-12-15 | — | — | EP | disclosed |
| EP-0750612-A1 | ACRIDONE-DERIVED BISINTERCALATORS AS CHEMOTHERAPEUTIC AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-01-02 | — | — | EP | disclosed |
| US-5508289-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | THE UNITED STATES AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995025093-A1 | ACRIDONE-DERIVED BISINTERCALATORS AS CHEMOTHERAPEUTIC AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-09-21 | — | — | WO | disclosed |
| US-5294631-A | Substituted benzimidazoles useful as angiotension II receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0525129-A4 | SUBSTITUTED BENZIMIDAZOLES | — | 1993-03-24 | — | — | EP | disclosed |
| EP-0525129-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991016313-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-31 | — | — | WO | disclosed |
| EP-0145226-B1 | SUBSTITUTED 1-AMINO-4-NITRO-ACRIDINONES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0138302-B1 | PYRAZOLO(3,4,5-KL)ACRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4705861-A | AZO DYE CHEMICAL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| EP-0114002-B1 | BENZOTHIOPYRANO(4,3,2,-CD)INDAZOLES, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4626540-A | Substituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with them | WARNER-LAMBERT COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4621086-A | Method of treating leukemia with pyrazolo[3,4,5-kl]acridines | WARNER-LAMBERT COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| US-4604390-A | FUNGICIDES, ANTITUMOR AGENTS | WARNER-LAMBERT COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0187231-A2 | Amino phenyl benzothiazoles | BAYER AG (DE) | 1986-07-16 | — | — | EP | disclosed |
| US-4588730-A | Pyrazolo[3,4,5-k1]acridine compositions and methods for their use as antimicrobials | WARNER-LAMBERT COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4582851-A | MICROBIOCIDES;LEUKEMIA;ANTITUMOR AND ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| US-4555572-A | Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use | WARNER-LAMBERT COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0152249-A2 | 1,4-Aminoalkylamino-9H-thioxanthen-9-ones, a process for the production of the compounds, an intermediate in the production of the compounds and a pharmaceutical composition comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-21 | — | — | EP | disclosed |
| EP-0145226-A2 | Substituted 1-amino-4-nitro-acridinones, pharmaceutical compositions comprising the same and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0138302-A1 | Pyrazolo(3,4,5-kl)acridine compounds, pharmaceutical compositions comprising the same and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
| EP-0114002-A2 | Benzothiopyrano(4,3,2,-cd)indazoles, their pharmaceutical compositions and methods for their production | WARNER-LAMBERT COMPANY (US) | 1984-07-25 | — | — | EP | disclosed |
| EP-0001246-B1 | PREPARATION OF 2-(3'- OR 4'-AMINOPHENYL)-5(OR 6)-AMINOBENZIMIDAZOLES | CASSELLA Aktiengesellschaft (DE) | 1981-02-25 | — | — | EP | disclosed |
| US-4192947-A | REACTING DIAMINO NITROBENZENE WITH NITROBENZOYL CHLORIDE, CYCLIZING ANILIDE IN AQUEOUS ALKALI, REDUCING NITRO GROUPS WITH SULFIDE | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-03-11 | — | — | US | disclosed |
| EP-0001246-A1 | Preparation of 2-(3'- or 4'-aminophenyl)-5(or 6)-aminobenzimidazoles | CASSELLA Aktiengesellschaft (DE) | 1979-04-04 | — | — | EP | disclosed |
| US-4059627-A | HYDROGENATION OF CHLORINATED NITRO AROMATIC, NOBLE METAL CATALYST, THIOETHER | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-22 | — | — | US | disclosed |
| US-4036838-A | Process for the production of nitro derivatives of aromatic compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
| US-4036838-A | Process for the production of nitro derivatives of aromatic compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | TDP1 2994/4885VCAM1 20/4885DPP4 1197/4885 |
| US-20180098541-A1 | MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | TDP1 638/4885VCAM1 4347/4885DPP4 763/4885 |
| US-20190166847-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | TDP1 738/4885VCAM1 4402/4885DPP4 606/4885 |
| US-20030220392-A1 | Fatty acid synthase inhibitors | FASN, FADS1, FADS2 | TDP1 3949/4885VCAM1 1461/4885DPP4 1500/4885 |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | TDP1 4669/4885VCAM1 45/4885DPP4 1686/4885 |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | TDP1 277/4885VCAM1 2144/4885DPP4 853/4885 |
| US-20070254312-A1 | Protein Kinase Inhibitors and Methods for Identiying Same | PRKCA, PRKCE, PRKCB | TDP1 1321/4885VCAM1 2867/4885DPP4 2241/4885 |
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | COMT, BPHL, PNMT | TDP1 2290/4885VCAM1 3903/4885DPP4 2106/4885 |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | AGPAT5, ACHE, GRIK5 | TDP1 1482/4885VCAM1 1261/4885DPP4 895/4885 |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TDP1 954/4885VCAM1 2956/4885DPP4 4591/4885 |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | TDP1 1571/4885VCAM1 4195/4885DPP4 4036/4885 |
| US-20140309208-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | CCL11, CCL2, CCL5 | TDP1 1975/4885VCAM1 60/4885DPP4 1203/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | TDP1 897/4885VCAM1 1356/4885DPP4 1843/4885 |
| US-10993440-B2 | Molecules having pesticidal utility, and intermediates, compositions, and processes related thereto | ACHE, DDT, MLYCD | TDP1 738/4885VCAM1 4402/4885DPP4 606/4885 |
| US-11944099-B2 | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto | ACHE, DDT, MLYCD | TDP1 683/4885VCAM1 4361/4885DPP4 576/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | TDP1 2994/4885VCAM1 20/4885DPP4 1197/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | TDP1 4669/4885VCAM1 45/4885DPP4 1686/4885 |
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | FLT3, CSF3R, ABL1 | TDP1 1785/4885VCAM1 2904/4885DPP4 1807/4885 |
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | TDP1 1741/4885VCAM1 4050/4885DPP4 1767/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | TDP1 277/4885VCAM1 2144/4885DPP4 853/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | TDP1 3338/4885VCAM1 2920/4885DPP4 2211/4885 |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | NFATC1, MYD88, ICOS | TDP1 1354/4885VCAM1 486/4885DPP4 3680/4885 |
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | TDP1 3212/4885VCAM1 1209/4885DPP4 3433/4885 |
| US-20050250796-A1 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | TNF, NOD2, LITAF | TDP1 4736/4885VCAM1 1138/4885DPP4 4726/4885 |
| US-20150374708-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | CCL11, CCL2, CCR1 | TDP1 2381/4885VCAM1 86/4885DPP4 1161/4885 |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | TDP1 653/4885VCAM1 3792/4885DPP4 3810/4885 |
| US-20110003859-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | BRAF, RAF1, ARAF | TDP1 2378/4885VCAM1 4138/4885DPP4 4566/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | TDP1 1182/4885VCAM1 4343/4885DPP4 1780/4885 |
| US-20040132694-A1 | Il-8 receptor antagonists | CXCL8, CCR8, TLR8 | TDP1 4343/4885VCAM1 259/4885DPP4 1319/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | TDP1 4502/4885VCAM1 27/4885DPP4 2434/4885 |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TDP1 633/4885VCAM1 3058/4885DPP4 4347/4885 |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TDP1 633/4885VCAM1 3058/4885DPP4 4347/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | TDP1 1331/4885VCAM1 2231/4885DPP4 3605/4885 |
| US-20210161144-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MLYCD | TDP1 683/4885VCAM1 4361/4885DPP4 576/4885 |
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCL2, CCR1, CCL11 | TDP1 2508/4885VCAM1 106/4885DPP4 1330/4885 |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCL2, CCL11, CCR1 | TDP1 2281/4885VCAM1 97/4885DPP4 1122/4885 |
| US-20250228239-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MLYCD | TDP1 683/4885VCAM1 4361/4885DPP4 576/4885 |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTP4A2, PTPRF, PTPA | TDP1 564/4885VCAM1 1539/4885DPP4 117/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | TDP1 4502/4885VCAM1 27/4885DPP4 2434/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | TDP1 4502/4885VCAM1 27/4885DPP4 2434/4885 |
| US-10258045-B2 | Molecules having pesticidal utility and intermediates, compositions and processes related thereto | ACHE, DDT, MLYCD | TDP1 657/4885VCAM1 4261/4885DPP4 609/4885 |
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | IL6, IL1A, IL1B | TDP1 4277/4885VCAM1 160/4885DPP4 4067/4885 |
| US-20060084661-A1 | IL-8 receptor antagonists | CXCL8, CCR8, TLR8 | TDP1 4343/4885VCAM1 259/4885DPP4 1319/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | TDP1 277/4885VCAM1 2144/4885DPP4 853/4885 |
| US-20030203916-A1 | 1,8-NAPHTHALIMIDE IMIDAZO{4,5,1-DE}ACRIDONES WITH ANTI-TUMOR ACTIVITY | MKI67, CDKN1A, CCNA1 | TDP1 815/4885VCAM1 2945/4885DPP4 1360/4885 |
| US-20030225125-A1 | IL-8 receptor antagonists | CXCL8, CCR8, ACKR3 | TDP1 4556/4885VCAM1 187/4885DPP4 1509/4885 |
| US-20240279233-A1 | MACROCYCLIC TAK1 INHIBITORS | TAB1, TBK1, IRAK3 | TDP1 1288/4885VCAM1 1953/4885DPP4 3912/4885 |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TDP1 715/4885VCAM1 3200/4885DPP4 4185/4885 |
| US-20190150452-A1 | MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | TDP1 638/4885VCAM1 4347/4885DPP4 763/4885 |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | TDP1 1741/4885VCAM1 4050/4885DPP4 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.